ERBB2 and breast cancer: Previously, trastuzumab was mainly used alone or in combination with chemotherapeutic agents to treat HER2-positive breast cancer, but is now also used in neoadjuvant and adjuvant therapies aimed at shrinking the size of tumors or reducing the risk of recurrence (Swain et al., 2023).